In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter ...

Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpoint; Planning to submit NDA under accelerated approval pathway in ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Discover how this common condition manifests, its impact on daily life, and the steps you can take to reclaim your vitality ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...